Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
AssigneeAmgen Inc.
InventorsSimon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
Life of this patent
Estimating the term…
Abstract
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Claims23
(canceled)
An isolated antibody that binds to an epitope that comprises at least three of amino acid residues 207, 208, 162, 164, 167, 132, 351, 390, 413, 123, 129, 311, 313, or 337 of SEQ ID NO:1.
An isolated antibody that binds to at least three of amino acid residues 207, 208, 162, 164, 167, 132, 351, 390, 413, 123, 129, 311, 313, or 337 of SEQ ID NO:1.
An isolated antibody that binds to at least four of amino acid residues 207, 208, 162, 164, 167, 132, 351, 390, 413, 123, 129, 311, 313, or 337 of SEQ ID NO:1.
An isolated human monoclonal neutralizing antibody that binds to an epitope of PCSK9 containing at least one of amino acids 162, 164, 167, 207 or 208 of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.